Spotlight on Hematology
Incorporating Best Practices and Advancing Therapeutic Options in the Treatment of Multiple Myeloma
StartActivity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio has no conflict of interest with any commercial interest(s) whose
products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio has no conflict of interest with any commercial interest(s) whose
products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Hematology Presentations
Expert Insights: Current and Future Directions in Chronic and Acute Leukemias
StartActivity Details
Expires: November 14, 2020
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with leukemia.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate clinical data for various TKI-based therapies in patients with CML, including newly diagnosed patients and those in later lines of therapy
- Assess various treatment strategies for patients with relapsed/refractory ALL, in consideration of salvage status, MRD, and cytogenetics
- Compare and contrast therapeutic approaches for newly diagnosed patients with AML, including patients who are both eligible and ineligible for intensive induction chemotherapy
Activity Description
Expert Insights is an accredited, videotaped discussion featuring Dr. Elias Jabbour and Dr. Susan O’Brien highlighting the most clinically relevant data on chronic and acute leukemias presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.
Statement of Educational Need
Several agents have changed the therapeutic landscape of leukemia (including CML, ALL, and AML), but despite their success, the search for new therapeutic options for these diseases is still important due to the emergence of primary or secondary resistance to treatment in patients and the difficulty of eradicating leukemia stem cells as the main “culprit” of the disease. Therefore, leukemia is still an important area of research aimed at improving the effectiveness of patient treatment. Clinicians must stay up to date of novel agents, combinations, and other strategies in order to maximize patient outcomes.
Topics of Discussion
- CML: Moving Next-Generation TKIs Into Earlier Lines of Therapy
- ALL: How Best to Manage Disease in the Relapsed/Refractory Setting
- AML: Selecting Therapy for Newly Diagnosed Patients
Faculty
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Grants/Research Support, Consultant: AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited
Associate Director for Clinical Services
Chao Family Comprehensive Cancer Center University of California Irvine Medical Center
Irvine, California
Consultant: Alexion, Amgen Inc., Aptose Biosciences Inc., Astellas Pharma US, Inc., Celgene Corporation, Eisai Co., Ltd., GlaxoSmithKline, Janssen Oncology, AbbVie Inc., Vaniam Group LLC, Verastem
Research Support: Acerta Pharma, Kite Pharma, Regeneron Pharmaceuticals
Consultant/Research Support: Gilead Sciences, Inc., Pharmacyclics LLC, TG Therapeutics, Pfizer Inc., Sunesis Pharmaceuticals, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity.
During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 14, 2020.
Statement of Commercial Support
This activity is supported by an independent educational grant from Pfizer Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
Activity Details
Expires: November 14, 2020
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with leukemia.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate clinical data for various TKI-based therapies in patients with CML, including newly diagnosed patients and those in later lines of therapy
- Assess various treatment strategies for patients with relapsed/refractory ALL, in consideration of salvage status, MRD, and cytogenetics
- Compare and contrast therapeutic approaches for newly diagnosed patients with AML, including patients who are both eligible and ineligible for intensive induction chemotherapy
Activity Description
Expert Insights is an accredited, videotaped discussion featuring Dr. Elias Jabbour and Dr. Susan O’Brien highlighting the most clinically relevant data on chronic and acute leukemias presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.
Statement of Educational Need
Several agents have changed the therapeutic landscape of leukemia (including CML, ALL, and AML), but despite their success, the search for new therapeutic options for these diseases is still important due to the emergence of primary or secondary resistance to treatment in patients and the difficulty of eradicating leukemia stem cells as the main “culprit” of the disease. Therefore, leukemia is still an important area of research aimed at improving the effectiveness of patient treatment. Clinicians must stay up to date of novel agents, combinations, and other strategies in order to maximize patient outcomes.
Topics of Discussion
- CML: Moving Next-Generation TKIs Into Earlier Lines of Therapy
- ALL: How Best to Manage Disease in the Relapsed/Refractory Setting
- AML: Selecting Therapy for Newly Diagnosed Patients
Faculty
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Grants/Research Support, Consultant: AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited
Associate Director for Clinical Services
Chao Family Comprehensive Cancer Center University of California Irvine Medical Center
Irvine, California
Consultant: Alexion, Amgen Inc., Aptose Biosciences Inc., Astellas Pharma US, Inc., Celgene Corporation, Eisai Co., Ltd., GlaxoSmithKline, Janssen Oncology, AbbVie Inc., Vaniam Group LLC, Verastem
Research Support: Acerta Pharma, Kite Pharma, Regeneron Pharmaceuticals
Consultant/Research Support: Gilead Sciences, Inc., Pharmacyclics LLC, TG Therapeutics, Pfizer Inc., Sunesis Pharmaceuticals, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity.
During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 14, 2020.
Statement of Commercial Support
This activity is supported by an independent educational grant from Pfizer Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
Incorporating Best Practices and Advancing Therapeutic Options in the Treatment of Multiple Myeloma
StartActivity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio has no conflict of interest with any commercial interest(s) whose
products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio has no conflict of interest with any commercial interest(s) whose
products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Evolving Approaches for the Management of Waldenström’s Macroglobulinemia
StartActivity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
- Describe the approved treatment paradigms for patients with WM
- Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Waldenström’s Macroglobulinemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Waldenström’s Macroglobulinemia , allowing for ease of assessment and incorporation into clinical practice.
Faculty
Fred Hutchinson Cancer Institute
Associate Professor, University of Washington
Seattle, WA
Edward Libby, MD, has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from BeiGene and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
- Describe the approved treatment paradigms for patients with WM
- Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Waldenström’s Macroglobulinemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Waldenström’s Macroglobulinemia , allowing for ease of assessment and incorporation into clinical practice.
Faculty
Fred Hutchinson Cancer Institute
Associate Professor, University of Washington
Seattle, WA
Edward Libby, MD, has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from BeiGene and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Expert Insights: Latest Approaches to Treating Lymphoma and Myeloma With CAR T-Cell Therapy
StartActivity Details
Expires: November 1, 2020
Jointly Provided By
This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.
Target Audience
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Explain the mechanism of action of CAR T-cell–based therapies and the rationale for their investigation and use in patients with lymphoma and multiple myeloma (MM)
- Evaluate clinical data of current and emerging CAR T-cell therapies for patients with lymphoma
- Assess clinical trial results from CAR T cells being investigated in patients with MM
- Anticipate adverse events (AEs) that may occur with CAR T-cell therapy and develop strategies to mitigate these AEs
Activity Description
Expert Insights is an accredited, videotaped discussion featuring Dr. Julie Vose and Dr. Bianca Santomasso highlighting the most clinically relevant data on lymphoma and myeloma presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.
Statement of Educational Need
CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.
Topics of Discussion
- Overview of CAR T Cells and Current Data of Patients with Lymphoma
- CAR T-Cell Therapy for Multiple Myeloma: The Future of Myeloma Care
- Ongoing Efforts to Improve the Safety of CAR T-cell therapy: Cytokine Release Syndrome and Neurotoxicity
Faculty
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE
Grant Support: Amgen, Acerta Pharma, AstraZeneca, Birstol Myers Squibb, Celgene, Incyte Corp., Kite Pharma, Merck, Novartis, Seattle Genetics
Consultant: AbbVie, Epizyme, Novartis, Roche, Legend Pharmaceuticals, Kyopharm, Sandoz, Vaniam Group LLC, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca, Nordic Nanovector, Verastem, Beigene
Neuro-Oncologist and Scientist
Memorial Sloan Kettering Cancer Center
New York, NY
Consultant: Kite/Gilead
Faculty and Planning Committee Disclosures
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
See faculty disclosures listed above.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Bio Ascend
planners and managers have nothing to disclose.
Accreditation Statement
Joint Accreditation Statement
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine and Bio Ascend.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity.
During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 1, 2020.
Statement of Commercial Support
This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Statement
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the continuing education of this activity, please contact Postgraduate Institute for Medicine (www.pimed.com) 1-800-423-3576 or email to inquiries@pimed.com
Activity Details
Expires: November 1, 2020
Jointly Provided By
This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.
Target Audience
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Explain the mechanism of action of CAR T-cell–based therapies and the rationale for their investigation and use in patients with lymphoma and multiple myeloma (MM)
- Evaluate clinical data of current and emerging CAR T-cell therapies for patients with lymphoma
- Assess clinical trial results from CAR T cells being investigated in patients with MM
- Anticipate adverse events (AEs) that may occur with CAR T-cell therapy and develop strategies to mitigate these AEs
Activity Description
Expert Insights is an accredited, videotaped discussion featuring Dr. Julie Vose and Dr. Bianca Santomasso highlighting the most clinically relevant data on lymphoma and myeloma presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.
Statement of Educational Need
CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.
Topics of Discussion
- Overview of CAR T Cells and Current Data of Patients with Lymphoma
- CAR T-Cell Therapy for Multiple Myeloma: The Future of Myeloma Care
- Ongoing Efforts to Improve the Safety of CAR T-cell therapy: Cytokine Release Syndrome and Neurotoxicity
Faculty
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE
Grant Support: Amgen, Acerta Pharma, AstraZeneca, Birstol Myers Squibb, Celgene, Incyte Corp., Kite Pharma, Merck, Novartis, Seattle Genetics
Consultant: AbbVie, Epizyme, Novartis, Roche, Legend Pharmaceuticals, Kyopharm, Sandoz, Vaniam Group LLC, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca, Nordic Nanovector, Verastem, Beigene
Neuro-Oncologist and Scientist
Memorial Sloan Kettering Cancer Center
New York, NY
Consultant: Kite/Gilead
Faculty and Planning Committee Disclosures
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
See faculty disclosures listed above.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Bio Ascend
planners and managers have nothing to disclose.
Accreditation Statement
Joint Accreditation Statement
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine and Bio Ascend.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity.
During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 1, 2020.
Statement of Commercial Support
This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Statement
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the continuing education of this activity, please contact Postgraduate Institute for Medicine (www.pimed.com) 1-800-423-3576 or email to inquiries@pimed.com
Podium to Practice: Updates from Chicago, Amsterdam, and Lugano Regarding Clinical Updates of Ongoing Trials in Chronic Lymphocytic Leukemia and Follicular Lymphoma
StartActivity Details
Expires: September 24, 2020
Jointly Provided By
This activity is jointly provided by The Postgraduate Institute for
Medicine and Bio Ascend.
Target Audience
The target audience for this activity is hematologists/oncologists, bone marrow transplant clinicians, and other healthcare professionals (oncology nurses and pharmacists, physician assistants, etc.) interested and/or involved in the treatment of patients with CLL/FL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review clinical trial data of current and emerging therapies that are being investigated in patients with CLL
- Evaluate the safety and efficacy data from clinical studies that are examining various treatment options and regimens in patients with FL
- Discuss common adverse events that are associated with these therapies, and develop approaches to mitigate such adverse events
- As new agents and regimens become available, develop strategies to safely and effectively integrate these treatment approaches in order to maximize patient outcomes
Activity Description
Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in the management and treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.
Statement of Educational Need
The management of FL and CLL is currently undergoing a dynamic, rapid, and very positive development. It is anticipated that the combination of targeted and non-chemotherapeutic drugs such as obinutuzumab, ibrutinib, idelalisib, and venetoclax will lead to deep, molecular, and long-lasting remissions. Clinicians will need to stay abreast of this changing landscape in order to offer their patients improved benefits, and potentially enroll eligible patients into clinical trials to examine novel therapies.
Topics of Discussion
- Clinical data of trials being performed in newly diagnosed patients with CLL or FL
- Trial results of agents being investigated in patients with relapsed/refractory CLL or FL
- Common AEs observed with investigational agents/regimens
- Strategies for integrating novel agents/regimens into practice that may be approved in the near future
Faculty
Director, Chronic Lymphocytic Leukemia Center
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Consulting Fees: Acerta Pharma, Celgene Corporation, Gilead Sciences, Inc., Pharmacyclics LLC, Sandoz
Associate Professor
Department of Medicine
Zucker School of Medicine at Hofstra/Northwell
CLL Research and Treatment Program
Feinstein Institutes for Medical Research
Northwell Health
New Hyde Park, New York
Consulting Fees: AbbVie Inc., Acerta Pharma, AstraZeneca, BeiGene, Catapult Therapeutics, Dynamo Therapeutics, Inc., Juno/Celgene, Kite Pharma, Octapharma AG, Novartis, Pharmacyclics LLC, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc., Verastem, Inc.
Honorarium: Janssen, Teva Contracted Research: Gilead Sciences, Inc., Loxo Oncology, Sun, Verastem, Inc.
Other (Data Safety Monitoring Committee): MorphoSys AG, Invectys
Disclosure of Conflicts of Interests
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Accreditation Statement
Joint Accreditation Statement
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine and Bio Ascend.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There is no fee for this educational activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Materials will be available online through September 24, 2020.
Statement of Commercial Support
This activity is supported by independent educational grants from Gilead Sciences, Inc. and Verastem, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
PIM and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of PIM and Bio Ascend.
Contact Information for Questions About the Activity
Activity Details
Expires: September 24, 2020
Jointly Provided By
This activity is jointly provided by The Postgraduate Institute for
Medicine and Bio Ascend.
Target Audience
The target audience for this activity is hematologists/oncologists, bone marrow transplant clinicians, and other healthcare professionals (oncology nurses and pharmacists, physician assistants, etc.) interested and/or involved in the treatment of patients with CLL/FL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review clinical trial data of current and emerging therapies that are being investigated in patients with CLL
- Evaluate the safety and efficacy data from clinical studies that are examining various treatment options and regimens in patients with FL
- Discuss common adverse events that are associated with these therapies, and develop approaches to mitigate such adverse events
- As new agents and regimens become available, develop strategies to safely and effectively integrate these treatment approaches in order to maximize patient outcomes
Activity Description
Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in the management and treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.
Statement of Educational Need
The management of FL and CLL is currently undergoing a dynamic, rapid, and very positive development. It is anticipated that the combination of targeted and non-chemotherapeutic drugs such as obinutuzumab, ibrutinib, idelalisib, and venetoclax will lead to deep, molecular, and long-lasting remissions. Clinicians will need to stay abreast of this changing landscape in order to offer their patients improved benefits, and potentially enroll eligible patients into clinical trials to examine novel therapies.
Topics of Discussion
- Clinical data of trials being performed in newly diagnosed patients with CLL or FL
- Trial results of agents being investigated in patients with relapsed/refractory CLL or FL
- Common AEs observed with investigational agents/regimens
- Strategies for integrating novel agents/regimens into practice that may be approved in the near future
Faculty
Director, Chronic Lymphocytic Leukemia Center
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Consulting Fees: Acerta Pharma, Celgene Corporation, Gilead Sciences, Inc., Pharmacyclics LLC, Sandoz
Associate Professor
Department of Medicine
Zucker School of Medicine at Hofstra/Northwell
CLL Research and Treatment Program
Feinstein Institutes for Medical Research
Northwell Health
New Hyde Park, New York
Consulting Fees: AbbVie Inc., Acerta Pharma, AstraZeneca, BeiGene, Catapult Therapeutics, Dynamo Therapeutics, Inc., Juno/Celgene, Kite Pharma, Octapharma AG, Novartis, Pharmacyclics LLC, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc., Verastem, Inc.
Honorarium: Janssen, Teva Contracted Research: Gilead Sciences, Inc., Loxo Oncology, Sun, Verastem, Inc.
Other (Data Safety Monitoring Committee): MorphoSys AG, Invectys
Disclosure of Conflicts of Interests
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Accreditation Statement
Joint Accreditation Statement
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine and Bio Ascend.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There is no fee for this educational activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Materials will be available online through September 24, 2020.
Statement of Commercial Support
This activity is supported by independent educational grants from Gilead Sciences, Inc. and Verastem, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
PIM and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of PIM and Bio Ascend.
Contact Information for Questions About the Activity
Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies
StartActivity Details
Expires: July 17, 2020
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Provider
This activity is jointly provided by the University of Nebraska Medical
Center, Center for Continuing Education and Bio Ascend.
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.
Learning Objectives
After completing this activity, participants should be better able to:
- Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
- Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
- Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events
Activity Description
Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.
Statement of Educational Need
CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.
Faculty
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska
Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois
Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Conflict of Interest Policy/Disclosure Statement
As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.
The following indicates the disclosure declaration information and the nature of those commercial relationships.
All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
Contact Information for Questions About the Activity
University of Nebraska Medical Center, Center for Continuing
Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250
Bio Ascend
cme@bioascend.com
Activity Details
Expires: July 17, 2020
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Provider
This activity is jointly provided by the University of Nebraska Medical
Center, Center for Continuing Education and Bio Ascend.
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.
Learning Objectives
After completing this activity, participants should be better able to:
- Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
- Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
- Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events
Activity Description
Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.
Statement of Educational Need
CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.
Faculty
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska
Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois
Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Conflict of Interest Policy/Disclosure Statement
As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.
The following indicates the disclosure declaration information and the nature of those commercial relationships.
All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
Contact Information for Questions About the Activity
University of Nebraska Medical Center, Center for Continuing
Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250
Bio Ascend
cme@bioascend.com
Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies
StartActivity Details
1.0 Contact Hour(s)
Expires: July 1, 2020
Accredited by
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Chronic Lymphocytic Leukemia.
Learning Objectives
After completing this program, participants should be able to:
1: Apply the latest data to risk stratify and optimize treatment plans for
patients with CLL based on prognostic and predictive markers
2: Differentiate between first-line and relapsed/refractory treatment
approaches for the treatment of CLL using the latest evidence-based
guidelines
3: Explain the emerging clinical data and ongoing trials on novel agents and
therapeutic strategies that have the potential to improve patient outcomes
for patients with CLL
4: Summarize evidence-based management strategies that can be used to
identify and treat acute and long-term complications associated with CLL
treatment including: barriers to treatment, adherence, comorbidities,
advanced age, etc.
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for CLL along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with CLL, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Jonathon B. Cohen, MD, MS, has disclosed having financial arrangements or
affiliations with the following commercial interest(s) whose products or
services may be mentioned in this activity.
Advisor: Janssen, Genentech
Research Funding: Genentech
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from AbbVie, Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and TG Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: July 1, 2020
Accredited by
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Chronic Lymphocytic Leukemia.
Learning Objectives
After completing this program, participants should be able to:
1: Apply the latest data to risk stratify and optimize treatment plans for
patients with CLL based on prognostic and predictive markers
2: Differentiate between first-line and relapsed/refractory treatment
approaches for the treatment of CLL using the latest evidence-based
guidelines
3: Explain the emerging clinical data and ongoing trials on novel agents and
therapeutic strategies that have the potential to improve patient outcomes
for patients with CLL
4: Summarize evidence-based management strategies that can be used to
identify and treat acute and long-term complications associated with CLL
treatment including: barriers to treatment, adherence, comorbidities,
advanced age, etc.
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for CLL along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with CLL, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Jonathon B. Cohen, MD, MS, has disclosed having financial arrangements or
affiliations with the following commercial interest(s) whose products or
services may be mentioned in this activity.
Advisor: Janssen, Genentech
Research Funding: Genentech
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from AbbVie, Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and TG Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
info@plexuscomm.com